论文部分内容阅读
目的:比较3种用药方案治疗2型糖尿病的疗效与成本,为临床合理用药提供依据。方法:回顾性分析86例2型糖尿病患者3种治疗方案(A组:二甲双胍片1.0～1.5g·d~(-1);B组:精蛋白生物合成人胰岛素30R注射液5～64u,早、晚餐前30minn ih;C组:二甲双胍片1.0～1.5g·d~(-1)+精蛋白生物合成人胰岛素30R注射液5～64u,早、晚餐前30mim ih),进行成本-效果比较。结果:A、B、C3组出院时血糖平均值差异无统计学意义(P>0.05),3组的血糖下降百分率分别为15.04%、17.96%、26.95%,C组与A、B组差异有统计学意义(P<0.05),A组与B、C组总成本的差异有统计学意义(p<0.05),A、B、C3组的总成本-效果比分别为65.63、69.66、48.46。B、C组相对于A组的增量总成本-效果比分别为90.41和26.77。结论:二甲双胍与精蛋白生物合成人胰岛素30R联合用药是2型糖尿病患者住院治疗成本效果较好的方案。
Objective: To compare the efficacy and cost of three kinds of medication regimens in the treatment of type 2 diabetes mellitus, and provide the basis for clinical rational drug use. Methods: Three kinds of treatment regimens were retrospectively analyzed in 86 patients with type 2 diabetes mellitus (group A: metformin 1.0 ~ 1.5g · d -1); group B: protamine biosynthesis human insulin 30R 5 ~ 64u , 30minn ih before dinner; C group: Metformin tablets 1.0 ~ 1.5g · d -1 + protamine biosynthesis of human insulin 30R injection 5 ~ 64u, early, before dinner 30mim ih), cost-effectiveness comparison. Results: There was no significant difference in the average blood glucose level at the time of discharge from group A, B and C3 (P> 0.05). The percentage of blood glucose in the three groups were 15.04%, 17.96% and 26.95%, respectively (P <0.05). There was significant difference between the total cost of group A and group B, C (p <0.05). The total cost-effect ratio of group A, B and C3 were 65.63, 69.66 and 48.46, respectively. The total incremental cost-effectiveness ratios of Group B and Group C relative to Group A were 90.41 and 26.77, respectively. CONCLUSION: The combination of metformin and protamine biosynthesis human insulin 30R is a better cost-effective treatment for type 2 diabetic patients.